Pipeline Report: January 2021
February 17th 2021
The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.
February 2nd 2021
Biond Biologics Ltd. will join Sanofi in an exclusive worldwide license agreement for the development and commercialization of the novel immunotherapy BND-22.